结核性葡萄膜炎的免疫反应及其治疗意义:从抗结核治疗到宿主导向治疗
本文综述结核性葡萄膜炎的免疫病理生理学及治疗进展,涵盖高负担与低负担结核国家以抗结核治疗为主要治疗手段的结果,并介绍肺结核领域宿主导向治疗(HDT)的进展及其应用于结核性葡萄膜炎的可能性。作者指出,HDT概念可能有助于指导未来结核性葡萄膜炎有效治疗的发展,但仍需对该病的免疫调节进行更深入研究。
要点
- 结核性葡萄膜炎临床表型多样,难以区分眼组织是否存在结核分枝杆菌(Mtb)、无Mtb侵入时是否引发增强免疫反应或抗视网膜自身免疫反应。
- 免疫病理学知识的不足可能延误及时诊断和适当管理。
- 肺结核领域宿主导向治疗(HDT)的进展可能为结核性葡萄膜炎治疗提供方向。
核心结论
- 宿主导向治疗(HDT)概念可能有助于指导未来结核性葡萄膜炎有效治疗的发展,但仍需对该病的免疫调节进行更深入研究。
研究设计与样本
- 本文为综述,总结结核性葡萄膜炎免疫病理生理学及治疗模式与结果的最新进展,涵盖高负担与低负担结核国家以抗结核治疗为主要治疗手段的结果,并概述肺结核领域宿主导向治疗(HDT)的进展。
主要发现
- 结核性葡萄膜炎临床表型多样,难以区分眼组织是否存在结核分枝杆菌(Mtb)、无Mtb侵入眼组织时是否引发增强免疫反应,或是否诱导抗视网膜自身免疫反应。
- 过去十年间,结核性葡萄膜炎的免疫病理生理学及临床管理(包括专家共识对特定情况是否采用抗结核治疗)已被广泛研究。
- 结核治疗研究总体正更多转向宿主导向治疗(HDT)。
- 鉴于宿主-Mtb相互作用的复杂性,增强宿主免疫反应预期可提高抗结核治疗的效果,并有助于克服人群中耐药Mtb菌株负担上升的问题。
局限性
- 仍需对该病的免疫调节进行更深入研究。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Tubercular uveitis (TB-uveitis) remains a conundrum in the uveitis field, which is mainly related to the diverse clinical phenotypes of TB-uveitis. Moreover, it remains difficult to differentiate whether Mycobacterium tuberculosis (Mtb) is present in the ocular tissues, elicits a heightened immune response without Mtb invasion in ocular tissues, or even induces an anti-retinal autoimmune response. Gaps in the immuno-pathological knowledge of TB-uveitis likely delay timely diagnosis and appropriate management. In the last decade, the immunopathophysiology of TB-uveitis and its clinical management, including experts' consensus to treat or not to treat certain conditions with anti-tubercular treatment (ATT), have been extensively investigated. In the meantime, research on TB treatment, in general, is shifting more toward host-directed therapies (HDT). Given the complexities of the host-Mtb interaction, enhancement of the host immune response is expected to boost the effectiveness of ATT and help overcome the rising burden of drug-resistant Mtb strains in the population. This review will summarize the current knowledge on the immunopathophysiology of TB-uveitis and recent advances in treatment modalities and outcomes of TB-uveitis, capturing results gathered from high- and low-burden TB countries with ATT as the mainstay of treatment. Moreover, we outline the recent progress of HDT development in the pulmonary TB field and discuss the possibility of its applicability to TB-uveitis. The concept of HDT might help direct future development of efficacious therapy for TB-uveitis, although more in-depth research on the immunoregulation of this disease is still necessary.
引用
- Putera I, Schrijver B, Ten Berge JCEM, et al. The immune response in tubercular uveitis and its implications for treatment: From anti-tubercular treatment to host-directed therapies. Prog Retin Eye Res. 2023. PMID: 37236420. doi:10.1016/j.preteyeres.2023.101189
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。